GlassScriptPhysician profile
Rachel E Messer
NPI 1447640628
$21,873.96
in general payments reported to CMS, 2019-2025
74 companies · $5,327 in 2025
The $5,327 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,096 · 2022: $5,227 · 2023: $3,610 · 2024: $3,614 · 2025: $5,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,285.03 |
| Education | $265.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,095.72 | 2021-2025 | |
| Pfizer INC. | $1,406.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,303.82 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $1,150.80 | 2021-2025 | Darzalex, Rybrevant, Talvey |
| Incyte Corporation | $1,034.57 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $795.57 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Celgene Corporation | $776.73 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $711.72 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Amgen INC. | $663.26 | 2021-2023 | Lumakras, Blincyto, Nplate |
| Eisai INC. | $658.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $632.40 | 2021-2025 | Imfinzi, Lynparza, Enhertu |
| Abbvie INC. | $609.53 | 2021-2025 | |
| Lilly USA, LLC | $595.85 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Csl Behring | $590.95 | 2021-2025 | Hizentra |
| Genzyme Corporation | $508.76 | 2021-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $496.32 | 2021-2025 | Keytruda, Reblozyl |
| Alexion Pharmaceuticals, INC. | $433.83 | 2021-2025 | Ultomiris, Soliris |
| Daiichi Sankyo INC. | $387.75 | 2022-2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $359.25 | 2021-2025 | Monoferric |
| Glaxosmithkline, LLC. | $357.94 | 2021-2025 | Ojjaara, Jemperli, Blenrep |
| Beigene USA, INC. | $353.10 | 2021-2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $349.72 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Bayer Healthcare Pharmaceuticals INC. | $337.88 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $295.93 | 2021-2025 | Libtayo |
| Stemline Therapeutics INC. | $272.35 | 2023-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $260.62 | 2021-2025 | |
| Genentech USA, INC. | $255.24 | 2021-2025 | Polivy, Tecentriq, Phesgo |
| Gilead Sciences, INC. | $242.56 | 2021-2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $241.33 | 2023-2025 | |
| Blueprint Medicines Corporation | $220.97 | 2021-2025 | Ayvakit |
| Sobi, INC | $206.00 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $196.64 | 2021-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $194.87 | 2021-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $178.85 | 2021-2024 | Somatuline Depot, Onivyde |
| Astellas Pharma US INC | $168.33 | 2021-2025 | Xtandi, Padcev |
| Array Biopharma INC | $158.59 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $140.60 | 2021-2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $130.11 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Morphosys, US INC. | $124.34 | 2022-2023 | Monjuvi |
| Puma Biotechnology, INC. | $121.94 | 2022-2025 | |
| Pharmaessentia USA Corporation | $110.71 | 2023-2025 | Besremi |
| Beone Medicines USA, INC. | $106.71 | 2025 | Tevimbra, Brukinsa |
| Acrotech Biopharma INC. | $106.42 | 2021-2023 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.06 | 2023-2025 | Gilotrif |
| Sumitomo Pharma America, INC. | $88.21 | 2023-2025 | Orgovyx |
| Spectrum Pharmaceuticals INC. | $87.62 | 2023-2025 | Rolvedon |
| Adc Therapeutics America, INC. | $87.37 | 2022-2025 | |
| Taiho Oncology, INC. | $85.72 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $83.65 | 2022-2023 | Fotivda |
| Exelixis INC. | $82.08 | 2022-2025 | Cabometyx |
| Progenics Pharmaceuticals, INC. | $80.38 | 2022-2023 | Pylarify |
| Recordati_rare_diseases_inc. | $77.02 | 2025 | Sylvant |
| Tempus Ai, INC | $53.85 | 2024 | |
| Agios Pharmaceuticals, INC. | $52.80 | 2023-2025 | Pyrukynd |
| Emd Serono, INC. | $48.03 | 2021-2022 | |
| Myovant Sciences INC. | $47.98 | 2022 | |
| Shield Therapeutics INC | $47.20 | 2024-2025 | |
| Global Blood Therapeutics, INC. | $45.95 | 2021-2022 | |
| Hema Biologics, LLC | $42.14 | 2023 | Sevenfact |
| Coherus Oncology, INC. | $41.01 | 2023-2025 | Loqtorzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.12 | 2025 | Relistor |
| Epizyme, INC. | $39.06 | 2022 | |
| Adaptive Biotechnologies Corporation | $36.72 | 2024 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $36.13 | 2021 | |
| Kyowa Kirin, INC. | $35.01 | 2021-2025 | |
| Genmab U.S., INC. | $34.05 | 2023-2024 | Epkinly |
| Eusa Pharma (US) LLC | $26.82 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.73 | 2025 | Danziten |
| Alnylam Pharmaceuticals INC. | $20.94 | 2025 | Givlaari |
| Apellis Pharmaceuticals, INC. | $20.43 | 2023 | Empaveli |
| Tersera Therapeutics LLC | $16.79 | 2021 | |
| Novocure INC. | $16.29 | 2025 | Optune Lua (Novottf-200t) |
| Amag Pharmaceuticals, INC. | $14.29 | 2021 | |
| Heron Therapeutics, INC. | $13.56 | 2021 |
Drugs and devices associated with these payments
Hizentra $486Reblozyl $469Darzalex $363Kisqali $357Lenvima $323Imfinzi $314Fruzaqla $301Jaypirca $298Padcev $279Verzenio $273Orserdu $272Xtandi $268Orgovyx $257Jakafi $256Opdivo $252Adcetris $251Rybrevant $245Enhertu $239Lutathera $234Ultomiris $232Imbruvica $228Talvey $225Qinlock $220Ninlaro $218Elrexfio $215Scemblix $202Libtayo $202Oxbryta $186Brukinsa $186Pluvicto $184Fabhalta $180Ojjaara $179Tecvayli $159Nubeqa $158Tukysa $154Monoferric $149Monjuvi $145Ayvakit $138Epkinly $129Iclusig $129Xofigo $119Carvykti $116Opdualag $115Besremi $111Voranigo $110Talzenna $103Venclexta $94.95Xpovio $94.73Promacta $90.69Rolvedon $87.62Trodelvy $87.07Doptelet $87.03Eliquis $86.58Romvimza $85.93Paxlovid $85.88Jemperli $84.25Polivy $82.57Vonjo $79.30Tibsovo $77.60Ibrance $77.41Sylvant $77.02Akeega $76.53Erleada $76.53Tevimbra $74.05Onivyde $73.77Somatuline Depot $73.77Braftovi $72.80Zepzelca $72.78Bosulif $71.51Retevmo $67.86Pomalyst $66.33Lorbrena $64.21Creon $60.92Relistor $59.82Beleodaq $59.07Stivarga $56.59Rezlidhia $56.27Tavalisse $56.27Tasigna $53.57Pyrukynd $52.80Hympavzi $50.84Cabometyx $50.46Soliris $49.73Piqray $47.97Tivdak $47.94Accrufer $47.20Blenrep $46.76Inlyta $45.59Mekinist $45.29Keytruda $45.27Mektovi $44.28Lynparza $43.95Sevenfact $42.14Elitek $41.65Sarclisa $41.65Tgct $40.38Balversa $37.95Inqovi $37.80Lonsurf $37.80Zynyz $37.67
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Messer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.